Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating restated by investment analysts at BMO Capital Markets in a report issued on Tuesday, November 7th. They presently have a $38.00 target price on the stock. BMO Capital Markets’ target price would indicate a potential upside of 12.29% from the stock’s previous close.
Several other brokerages have also recently weighed in on AZN. Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, September 22nd. Investec raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Leerink Swann lowered shares of Astrazeneca from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $36.00 to $31.00 in a research note on Thursday, July 27th. Argus reiterated a “buy” rating and issued a $35.00 price target on shares of Astrazeneca in a research note on Friday, September 1st. Finally, Goldman Sachs Group Inc restated a “sell” rating on shares of Astrazeneca in a research note on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $34.20.
Astrazeneca (AZN) traded up $0.02 during trading on Tuesday, reaching $33.84. 955,937 shares of the company were exchanged, compared to its average volume of 2,901,476. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 1.09. The company has a market cap of $85,679.36, a price-to-earnings ratio of 8.08, a PEG ratio of 3.20 and a beta of 0.75. Astrazeneca has a twelve month low of $25.55 and a twelve month high of $35.60.
Several institutional investors have recently added to or reduced their stakes in AZN. Meeder Asset Management Inc. purchased a new position in Astrazeneca during the second quarter worth $105,000. WFG Advisors LP boosted its stake in shares of Astrazeneca by 36.0% during the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock valued at $127,000 after purchasing an additional 984 shares during the period. Valeo Financial Advisors LLC purchased a new stake in shares of Astrazeneca during the third quarter valued at $133,000. Bronfman E.L. Rothschild L.P. boosted its stake in shares of Astrazeneca by 71.2% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock valued at $145,000 after purchasing an additional 1,769 shares during the period. Finally, Quadrant Capital Group LLC lifted its stake in Astrazeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after acquiring an additional 846 shares during the period. Hedge funds and other institutional investors own 14.44% of the company’s stock.
WARNING: “BMO Capital Markets Reaffirms Buy Rating for Astrazeneca PLC (AZN)” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/bmo-capital-markets-reaffirms-buy-rating-for-astrazeneca-plc-azn/1763573.html.
Astrazeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with our FREE daily email newsletter.